We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

95 hedge funds and large institutions have $141M invested in Sciclone Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 41 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more call options, than puts

Call options by funds: $409K | Put options by funds: $163K

16% more capital invested

Capital invested by funds: $122M → $141M (+$19M)

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

1% less funds holding

Funds holding: 9695 (-1)

41% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 41

Holders
95
Holders Change
-1
Holders Change %
-1.04%
% of All Funds
2.73%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
24
Reduced
41
Closed
14
Calls
$409K
Puts
$163K
Net Calls
+$246K
Net Calls Change
+$377K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$24.6M +$4.96M +1,019,282 +28%
LSV Asset Management
2
LSV Asset Management
Illinois
$13.1M -$288K -59,106 -2%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$12.1M +$630K +129,396 +6%
BIT
4
BlackRock Institutional Trust
California
$12.1M -$1.5M -308,645 -12%
BFA
5
BlackRock Fund Advisors
California
$10.1M -$1.28M -263,431 -12%
NCM
6
Nantahala Capital Management
Connecticut
$9.68M +$377K +77,577 +4%
Vanguard Group
7
Vanguard Group
Pennsylvania
$7.67M +$579 +119 +0%
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$6.48M +$1.15M +236,029 +24%
State Street
9
State Street
Massachusetts
$5.14M -$86.7K -17,822 -2%
QBFM
10
QS Batterymarch Financial Management
New York
$4.32M -$435K -89,350 -10%
Northern Trust
11
Northern Trust
Illinois
$3.3M -$426K -87,487 -12%
BA
12
BlackRock Advisors
Delaware
$1.99M -$1.24M -254,936 -40%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$1.8M -$30.6K -6,292 -2%
Renaissance Technologies
14
Renaissance Technologies
New York
$1.69M +$284K +58,319 +22%
Wellington Management Group
15
Wellington Management Group
Massachusetts
$1.38M -$250K -51,300 -16%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.36M +$19.2K +3,942 +2%
TCIM
17
TIAA CREF Investment Management
New York
$1.15M -$222K -45,551 -17%
PP
18
PDT Partners
New York
$1.14M
Norges Bank
19
Norges Bank
Norway
$1.14M +$525K +107,991 +100%
Connor, Clark & Lunn Investment Management (CC&L)
20
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.03M +$47.2K +9,700 +6%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$877K
BCM
22
Bridgeway Capital Management
Texas
$877K +$23.8K +4,900 +3%
Bank of America
23
Bank of America
North Carolina
$861K +$96.8K +19,900 +14%
BIM
24
BlackRock Investment Management
Delaware
$831K -$14.1K -2,904 -2%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$759K +$3.89K +800 +0.6%

SCLN Hedge Fund Activity: Q2 2014 in Review

95 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2014, worth a combined $141M — up 16% from $122M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SCLN and 13 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 24 added.

The largest buyer was Franklin Resources, adding an estimated $4.96M. The largest seller was BlackRock Institutional Trust, cutting an estimated $1.5M.

  • 95 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2014, down from 96 in Q1 2014.
  • Funds reported $141M of Sciclone Pharmaceuticals Inc stock for Q2 2014, up 16% quarter-over-quarter.
  • 13 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2014 and 14 closed out, a net change of -1 holder.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q2 2014 was Franklin Resources, an estimated $4.96M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q2 2014 was BlackRock Institutional Trust, an estimated $1.5M sold.

Based on aggregated 13F filings for Q2 2014.